ABSTRACT

Hepatocellular carcinoma (HCC) is a primary liver cancer that poses a substantial worldwide health challenge. It is frequently linked to underlying liver illnesses, most notably chronic liver inflammation and cirrhosis. Regular monitoring of high-risk individuals, such as those with chronic liver illnesses, is critical for early intervention and improved results. HCC is a critical illness for which early detection and treatment are critical. With its rising prevalence and frequent late-stage diagnosis, there is an urgent need for better curative therapy. Recent advances in systemic therapy, including as immune checkpoint inhibitors and tailored medicines, are showing promise in the treatment of HCC. Curative therapy for HCC have advanced tremendously, with a range of approaches customised to individual patient features and disease stages now available. On-going research into developing therapeutics holds the prospect of broadening the curative armamentarium for HCC, providing hope for enhanced survival and quality of life for those affected. This review provides in-depth look at curative approaches and new therapeutics for HCC. Keywords: Hepatocellular Carcinoma, liver transplantation, Resection, Chemotherapy, Radiotherapy
Publication date: 01/12/2024

https://ijbpas.com/pdf/2024/December/MS_IJBPAS_2024_8512.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.12.8512